Abstract P5-15-02: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

Triple Negative ◽

Eribulin Mesylate ◽

Faculty Opinions recommendation of Abstract P5-15-02: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735554384.793559073 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Eribulin Mesylate ◽

Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

10.1158/1538-7445.sabcs17-pd6-13 ◽

2018 ◽

Cited By ~ 11

Author(s):

SM Tolaney ◽

K Kalinsky ◽

V Kaklamani ◽

C Savulsky ◽

M Olivo ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Eribulin Mesylate ◽

Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(17)30131-4 ◽

2017 ◽

Vol 72 ◽

pp. S16 ◽

Cited By ~ 11

Author(s):

S. Tolaney ◽

C. Savulsky ◽

G. Aktan ◽

D. Xing ◽

A. Almonte ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Eribulin Mesylate ◽

Abstract OT1-03-19: Design of a phase 1b/2 study to evaluate the efficacy and safety of eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

10.1158/1538-7445.sabcs15-ot1-03-19 ◽

2016 ◽

Cited By ~ 1

Author(s):

E Berrak ◽

G Atkan ◽

J Song ◽

A Almonte ◽

V Karantza ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Efficacy And Safety ◽

Eribulin Mesylate ◽

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

Cancer Medicine ◽

10.1002/cam4.1705 ◽

2018 ◽

Vol 7 (9) ◽

pp. 4371-4378 ◽

Cited By ~ 5

Author(s):

Sarah S. Mougalian ◽

Ronda Copher ◽

Jonathan K. Kish ◽

Lindsay McAllister ◽

Zhixiao Wang ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Benefit ◽

Triple Negative ◽

Long Term Outcomes ◽

Eribulin Mesylate ◽

Community Oncology ◽

The Us

Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)

10.1158/1535-7163.targ-15-c166 ◽

2015 ◽

Cited By ~ 1

Author(s):

Thomas M. Cardillo ◽

Serengulam V. Govindan ◽

Maria Zalath ◽

Roberto Arrojo ◽

Robert M. Sharkey ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Parp Inhibitor ◽

Therapeutic Outcome ◽

Eribulin Mesylate ◽

Microtubule Inhibitors

Abstract P6-02-04: Eribulin mesylate promotes a mesenchymal-epithelial transition (MET) and effectively radio-sensitizes triple negative breast cancer cells

10.1158/1538-7445.sabcs14-p6-02-04 ◽

2015 ◽

Author(s):

Eileen P Connolly ◽

Youping Sun ◽

Tom K Hei

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Triple Negative ◽

Eribulin Mesylate ◽

Mesenchymal Epithelial Transition

Abstract P1-03-09: Pegylated recombinant human hyaluronidase PH20 (PEGPH20) enhances efficacy of eribulin mesylate (HALAVEN®) in triple negative breast cancer xenografts

10.1158/1538-7445.sabcs15-p1-03-09 ◽

2016 ◽

Author(s):

JD Bahn ◽

C DesJardins ◽

KB Condon ◽

A Fathallah ◽

S Zimmerman ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Eribulin Mesylate ◽

Recombinant Human Hyaluronidase ◽

Breast Cancer Xenografts

Abstract P3-09-15: A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response

10.1158/1538-7445.sabcs19-p3-09-15 ◽

2020 ◽

Author(s):

Steven J Isakoff ◽

Sylvia Adams ◽

Hatem H Soliman ◽

Nadine Tung ◽

William T Barry ◽

...

Keyword(s):

Breast Cancer ◽

Immune Response ◽

Adjuvant Therapy ◽

Triple Negative ◽

Early Stage ◽

Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

10.1158/1538-7445.sabcs19-pd1-06 ◽

2020 ◽

Cited By ~ 2

Author(s):

Hyo (Heather) Han ◽

Sami Diab ◽

Carlos Alemany ◽

Reva Basho ◽

Ursa Brown-Glaberman ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase 1B ◽

First Line Treatment